Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.
Industry sector: Medical
Sector classification: Biological products, except diagnostic
Deep Learning based analysis and prediction model for Biogen Idec Inc. (BIIB) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 2, 2015.
Market data for BIIB model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are
accounted for in this model in the form of the historical data coincided with outbreaks and other
global events in the past used to train ML prediction model for BIIB.
Model is being retrained on a daily basis.
| Float | 210M |
| P/E | 12.10 |
| Shares Outstanding | 211M |
| % Held by Insiders | 0.25% |
| % Held by Institutions | 89.00% |
| EPS (last reported FY) | $21.81 |
| EPS (last reported Q) | $6.05 |
| EPS, estimated (last reported Q) | $5.93 |
| Total revenues | $12 B |
| Net income | $3 B |